MHS MD - Clene Head Medical
| CLNN Stock | USD 4.15 0.27 6.96% |
Executive
MHS MD is Head Medical of Clene Inc
| Address | 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121 |
| Phone | 801 676 9695 |
| Web | https://clene.com |
Clene Management Efficiency
The company has return on total asset (ROA) of (0.4171) % which means that it has lost $0.4171 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8966) %, meaning that it created substantial loss on money invested by shareholders. Clene's management efficiency ratios could be used to measure how well Clene manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.99. In addition to that, Return On Capital Employed is likely to drop to -1.58. At this time, Clene's Fixed Asset Turnover is very stable compared to the past year.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Pattie Chiang | Kezar Life Sciences | N/A | |
| Roee Shahar | Immunome | N/A | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Saurabh Sewak | Foghorn Therapeutics | N/A | |
| Bruce MD | Immunome | 60 | |
| Moses Makunje | Nuvation Bio | 45 | |
| Kristian MBA | Foghorn Therapeutics | 48 | |
| Edward Horst | Sensei Biotherapeutics | 50 | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| William Winston | Werewolf Therapeutics | N/A | |
| Bob Lally | Ikena Oncology | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Gitanjali Jain | Kezar Life Sciences | N/A | |
| Kevin Shaw | NextCure | 49 | |
| Neel Anand | Kezar Life Sciences | N/A | |
| Stacy Rollinger | NextCure | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Marianna Zipeto | Champions Oncology | N/A | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| David MD | Nkarta Inc | 46 | |
| FACP MD | Sensei Biotherapeutics | N/A | |
Management Performance
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.42 |
Clene Inc Leadership Team
Elected by the shareholders, the Clene's board of directors comprises two types of representatives: Clene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clene. The board's role is to monitor Clene's management team and ensure that shareholders' interests are well served. Clene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert MD, Chief Officer | ||
| CPA CPA, Chief Officer | ||
| Tae Mgt, Consultant | ||
| Mark ESQ, Chief Officer | ||
| Michael Hotchkin, Chief Officer | ||
| Robert MBA, President CEO | ||
| Mark Mortenson, CoFounder Officer | ||
| Mary Mcneil, Head Resources | ||
| MHS MD, Head Medical | ||
| Jerry JD, General Secretary |
Clene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.42 | ||||
| Operating Margin | (81.22) % | ||||
| Current Valuation | 41.35 M | ||||
| Shares Outstanding | 7.98 M | ||||
| Shares Owned By Insiders | 28.28 % | ||||
| Shares Owned By Institutions | 12.91 % | ||||
| Number Of Shares Shorted | 160.4 K | ||||
| Price To Earning | 4.09 X | ||||
| Price To Book | 7.83 X |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clene Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clene. If investors know Clene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.614 | Earnings Share (5.29) | Revenue Per Share 0.069 | Quarterly Revenue Growth (0.66) | Return On Assets (0.42) |
The market value of Clene Inc is measured differently than its book value, which is the value of Clene that is recorded on the company's balance sheet. Investors also form their own opinion of Clene's value that differs from its market value or its book value, called intrinsic value, which is Clene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clene's market value can be influenced by many factors that don't directly affect Clene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.